Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Depreciation and Depletion: 2015-2017

Historic Depreciation and Depletion for Intellia Therapeutics (NTLA) over the last 3 years, with Dec 2017 value amounting to $3.0 million.

  • Intellia Therapeutics' Depreciation and Depletion rose 252.94% to $660,000 in Q1 2017 from the same period last year, while for Mar 2017 it was $1.6 million, marking a year-over-year increase of 246.48%. This contributed to the annual value of $3.0 million for FY2017, which is 172.73% up from last year.
  • According to the latest figures from FY2017, Intellia Therapeutics' Depreciation and Depletion is $3.0 million, which was up 172.73% from $1.1 million recorded in FY2016.
  • In the past 5 years, Intellia Therapeutics' Depreciation and Depletion registered a high of $3.0 million during FY2017, and its lowest value of $300,000 during FY2015.
  • In the last 3 years, Intellia Therapeutics' Depreciation and Depletion had a median value of $1.1 million in 2016 and averaged $1.5 million.
  • Data for Intellia Therapeutics' Depreciation and Depletion shows a peak YoY soared of 266.67% (in 2016) over the last 5 years.
  • Intellia Therapeutics' Depreciation and Depletion (Yearly) stood at $300,000 in 2015, then spiked by 266.67% to $1.1 million in 2016, then spiked by 172.73% to $3.0 million in 2017.